주의력결핍 과잉행동장애(ADHD) 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Attention Deficit Hyperactivity Disorder Market is presumed to reach the market size of nearly USD 28 Billion by 2032 from USD 19.32 Billion in 2023 with a CAGR of 4.21% under the study period 2024-2032.

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition featuring symptoms of hyperactivity, inattention, and impulsivity, which can disrupt daily functioning. It commonly presents in childhood but can continue into adulthood. Individuals with ADHD find it challenging to sustain attention, accomplish tasks, organize activities, and regulate impulses. The exact cause of ADHD is not wholly understood but is believed to involve genetic, environmental, and neurological factors. Diagnosis typically relies on clinical evaluation and behavioral assessments. Treatment often includes behavioral therapy, medication, and lifestyle adjustments to help manage symptoms and improve quality of life.

MARKET DYNAMICS

The attention deficit hyperactivity disorder (ADHD) market is primarily driven by the rising prevalence of ADHD diagnoses among children and adults. Increased awareness and better understanding of ADHD symptoms have led to more individuals seeking medical help and receiving diagnoses. The spurring acceptance of mental health issues and the reduction of stigma surrounding ADHD have also contributed to market growth. Furthermore, advancements in pharmaceutical treatments and new medications with enhanced efficacy and fewer side effects have boosted the market. Expanding behavioral therapies and support services for ADHD patients complements medical treatments, driving comprehensive market growth. Additionally, increasing research & development activities aimed at understanding the genetic and environmental factors of ADHD are propelling the attention deficit hyperactivity disorder market forward. However, stigma and misdiagnosis issues may challenge the attention deficit hyperactivity disorder market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Attention Deficit Hyperactivity Disorder. The growth and trends of Attention Deficit Hyperactivity Disorder industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Attention Deficit Hyperactivity Disorder market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

• Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate)
• Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others)

By Demographics

• Children
• Adults

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Attention Deficit Hyperactivity Disorder market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Attention Deficit Hyperactivity Disorder market include Novartis AG, Eli Lilly And Company, Johnson & Johnson Services Inc., Lupin, Takeda Pharmaceutical Company Limited, Mallinckrodt Plc., Pfizer Inc., Purdue Pharma L.P., Aytu BioPharma Inc. (NEOS Therapeutics Inc.), Supernus Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ATTENTION DEFICIT HYPERACTIVITY DISORDER - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Type
  • 3.7.2 Market Attractiveness Analysis By Demographics
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DRUG TYPE

• 5.1. Overview By Drug Type
• 5.2. Historical and Forecast Data Analysis By Drug Type
• 5.3. Stimulants (Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate) Historic and Forecast Sales By Regions
• 5.4. Non-stimulants (Atomoxetine, Guanfacine, Clonidine, Others) Historic and Forecast Sales By Regions

6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DEMOGRAPHICS

• 6.1. Overview By Demographics
• 6.2. Historical and Forecast Data Analysis By Demographics
• 6.3. Children Historic and Forecast Sales By Regions
• 6.4. Adults Historic and Forecast Sales By Regions

7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Retail Pharmacy Historic and Forecast Sales By Regions
• 7.4. Hospital Pharmacy Historic and Forecast Sales By Regions

8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ATTENTION DEFICIT HYPERACTIVITY DISORDER COMPANIES

• 9.1. Attention Deficit Hyperactivity Disorder Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF ATTENTION DEFICIT HYPERACTIVITY DISORDER INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Novartis AG
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Eli Lilly And Company
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Johnson & Johnson Services Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Lupin
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Takeda Pharmaceutical Company Limited
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Mallinckrodt Plc.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Pfizer Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Purdue Pharma L.P.
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Aytu BioPharma Inc. (NEOS Therapeutics Inc.)
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Supernus Pharmaceuticals Inc
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies